10.06MMarket Cap-0.17P/E (TTM)
0.6168High0.5801Low333.53KVolume0.5900Open0.5757Pre Close200.22KTurnover2.40%Turnover RatioLossP/E (Static)16.32MShares21.600052wk High0.74P/B8.56MFloat Cap0.568252wk Low--Dividend TTM13.88MShs Float100075500.0000Historical High--Div YieldTTM6.37%Amplitude0.5682Historical Low0.6000Avg Price1Lot Size
Jaguar Health Stock Forum
Acquisition Target? Why Jaguar Health Just Activated Its Defensive Measures
Rare Disease Breakthrough? Jaguar's Drug Gets Double European Green Light
Jaguar Health's Cholera Drug Could Unlock $350M FDA Voucher as WHO Declares Emergency
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Tuesday, 18th February at 9:00 am
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million
1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide
SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Jaguar Health, Inc. (NASDAQ: ...
Accesswire· 4 mins ago
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million
1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide
I very much look forward to providing an overview of Magdalena at this conference and meeting with potential partners and investors at this event," Dr. Brunke said. "We expect Magdalena's lead botanical drug candidate, MB2500, to soon be IND-enabled for one of the following indications: cognitive deficit in schizophrenia or executive ...
No comment yet